Dr. John Cush RheumNow
2 years 1 month ago
Difficult-to-Treat Psoriasis
This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.
https://t.co/OWzmYShqBs https://t.co/u1995MAB15
Dr. John Cush RheumNow
2 years 1 month ago
Low Back Pain? Take a Walk!
A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
https://t.co/FTm69VviD1 https://t.co/q53EIxAc1J
Dr. John Cush RheumNow
2 years 1 month ago
RT: @synovialjoints In a Swedish-Danish cohort study on patients with PsA, treatment with TNFi was associated with a small increased risk of NMSC and with non-significant numeric risk increases for both BCC and SCC compared with bDMARD naïve #EULAR2024 Abstract 0150
Dr. John Cush RheumNow
2 years 1 month ago
RT: @aurelierheumo
TOLERA trial in RA
RTX/ABA sequence versus RTX alone
10pts each group
Primary outcome was ambitious: ACPA seroconversion
No difference between ttmts (and also no seroconversion)
No diff in disease activity
No diff in ACPA change wt wk52
OP0069 #EULAR2024
The New England Journal of Medicine has published a review of systemic amyloidosis. "Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, and hepatomegaly."
Dr. John Cush RheumNow
2 years 1 month ago
RT @yuz6yusof #EULAR2024 Cutaneous #lupus is variable & can be difficult to treat. Promising post-hoc data frm Phase 2 RCT showing Deucravacitinib (Tyk2-i) led to improvement & sustained CLASI-50 response in all subtypes (ACLE, SCLE, Chonic and Discoid) #EULARBEST
Dr. John Cush RheumNow
2 years 1 month ago
Vilobelimab, an anticomplement factor 5a (C5a) antibody, shown in this case report to be effective in (difficult to treat) pyoderma gangrenosum. https://t.co/P241Knoco6 https://t.co/hrCxOv8SEA
Dr. John Cush RheumNow
2 years 1 month ago
Prevention of Psoriatic Arthritis
Dr. Peter Nash sharing his perspectives on preventing psoriasis from turning into PsA at Eular 2024 in Vienna, Austria.
https://t.co/DQJ5AcwchL https://t.co/lHtCt720D9
Dr. John Cush RheumNow
2 years 1 month ago
Digital Rheumatology
Dr. Jonathan Kay reviews abstracts POS0451 and POS0607 presented at Eular 2024 in Vienna, Austria.
https://t.co/9twSiXYL3N https://t.co/9vz77SrVLt
Dr. John Cush RheumNow
2 years 1 month ago
Late “Breaking”: Reducing Osteoporotic Fractures in Postmenopausal Women
Dr. Janet Pope discusses abstract POS0583 presented at Eular 2024 in Vienna, Austria.
https://t.co/HIXV4EUkJb https://t.co/p38e6pzAvC
Dr. John Cush RheumNow
2 years 1 month ago
Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis
https://t.co/QKXUxyhPUd https://t.co/Lx0VrBGqtg
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
